71 related articles for article (PubMed ID: 30213813)
1. Longitudinal Persistence of Meningeal Enhancement on Postcontrast 7T 3D-FLAIR MRI in Multiple Sclerosis.
Jonas SN; Izbudak I; Frazier AA; Harrison DM
AJNR Am J Neuroradiol; 2018 Oct; 39(10):1799-1805. PubMed ID: 30213813
[TBL] [Abstract][Full Text] [Related]
2. Identifying a new subtype of multiple sclerosis.
Trapp BD; Ontaneda D
Neurodegener Dis Manag; 2018 Dec; 8(6):367-369. PubMed ID: 30215581
[TBL] [Abstract][Full Text] [Related]
3. Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era.
Kister I; Bacon TE; Cutter GR
Ther Adv Neurol Disord; 2018; 11():1756286418793613. PubMed ID: 30214486
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
Healy BC; Glanz BI; Zurawski JD; Mazzola M; Chitnis T; Weiner HL
J Neurol Sci; 2018 Nov; 394():127-131. PubMed ID: 30248571
[TBL] [Abstract][Full Text] [Related]
5. Leveraging technology to identify subclinical deficits in radiologically isolated syndrome.
Okuda DT
Eur J Neurol; 2019 Jan; 26(1):3-4. PubMed ID: 30221805
[No Abstract] [Full Text] [Related]
6. The relevance of ceramides and their synthesizing enzymes for multiple sclerosis.
Kurz J; Brunkhorst R; Foerch C; Blum L; Henke M; Gabriel L; Ulshöfer T; Ferreirós N; Parnham MJ; Geisslinger G; Schiffmann S
Clin Sci (Lond); 2018 Sep; 132(17):1963-1976. PubMed ID: 30219773
[TBL] [Abstract][Full Text] [Related]
7. Myelination induction by a histamine H3 receptor antagonist in a mouse model of preterm white matter injury.
Rangon CM; Schang AL; Van Steenwinckel J; Schwendimann L; Lebon S; Fu T; Chen L; Beneton V; Journiac N; Young-Ten P; Bourgeois T; Maze J; Matrot B; Baburamani AA; Supramaniam V; Mallard C; Trottet L; Edwards AD; Hagberg H; Fleiss B; Li J; Chuang TT; Gressens P
Brain Behav Immun; 2018 Nov; 74():265-276. PubMed ID: 30218783
[TBL] [Abstract][Full Text] [Related]
8. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
9. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course.
Gil-Varea E; Urcelay E; Vilariño-Güell C; Costa C; Midaglia L; Matesanz F; Rodríguez-Antigüedad A; Oksenberg J; Espino-Paisan L; Dessa Sadovnick A; Saiz A; Villar LM; García-Merino JA; Ramió-Torrentà L; Triviño JC; Quintana E; Robles R; Sánchez-López A; Arroyo R; Alvarez-Cermeño JC; Vidal-Jordana A; Malhotra S; Fissolo N; Montalban X; Comabella M
J Neuroinflammation; 2018 Sep; 15(1):265. PubMed ID: 30217166
[TBL] [Abstract][Full Text] [Related]
10. Meningeal contrast enhancement in multiple sclerosis: Assessment of field strength, acquisition delay, and clinical relevance.
Harrison DM; Allette YM; Zeng Y; Cohen A; Dahal S; Choi S; Zhuo J; Hua J
PLoS One; 2024; 19(5):e0300298. PubMed ID: 38809920
[TBL] [Abstract][Full Text] [Related]
11. Meningeal contrast enhancement in multiple sclerosis: assessment of field strength, acquisition delay, and clinical relevance.
Harrison DM; Allette YM; Zeng Y; Cohen A; Dahal S; Choi S; Zhuo J; Hua J
medRxiv; 2024 Mar; ():. PubMed ID: 38496664
[TBL] [Abstract][Full Text] [Related]
12. Imaging of brain barrier inflammation and brain fluid drainage in human neurological diseases.
Okar SV; Fagiani F; Absinta M; Reich DS
Cell Mol Life Sci; 2024 Jan; 81(1):31. PubMed ID: 38212566
[TBL] [Abstract][Full Text] [Related]
13. Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation.
Oh J; Airas L; Harrison D; Järvinen E; Livingston T; Lanker S; Malik RA; Okuda DT; Villoslada P; de Vries HE
Front Neurol; 2023; 14():1319869. PubMed ID: 38107636
[TBL] [Abstract][Full Text] [Related]
14. A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis.
Dahal S; Allette YM; Naunton K; Harrison DM
Mult Scler Relat Disord; 2024 Jan; 81():105344. PubMed ID: 38035495
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Pathophysiology and Magnetic Resonance Imaging of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
Cacciaguerra L; Rocca MA; Filippi M
Korean J Radiol; 2023 Dec; 24(12):1260-1283. PubMed ID: 38016685
[TBL] [Abstract][Full Text] [Related]
16. Highly Sensitive 3-Tesla Real Inversion Recovery MRI Detects Leptomeningeal Contrast Enhancement in Chronic Active Multiple Sclerosis.
Okar SV; Dieckhaus H; Beck ES; Gaitán MI; Norato G; Pham DL; Absinta M; Cortese IC; Fletcher A; Jacobson S; Nair G; Reich DS
Invest Radiol; 2024 Mar; 59(3):243-251. PubMed ID: 37493285
[TBL] [Abstract][Full Text] [Related]
17. Use of a Commercial 7-T MRI Scanner for Clinical Brain Imaging: Indications, Protocols, Challenges, and Solutions-A Single-Center Experience.
Özütemiz C; White M; Elvendahl W; Eryaman Y; Marjańska M; Metzger GJ; Patriat R; Kulesa J; Harel N; Watanabe Y; Grant A; Genovese G; Cayci Z
AJR Am J Roentgenol; 2023 Dec; 221(6):788-804. PubMed ID: 37377363
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
